Inside the push to get weight loss treatment covered by Medicare Reuters reported that the medications, which fall into the GLP-1 agonist class of drugs, have been shown to help reduce a person ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

President Joe Biden's proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity ...

The drug coverage provision does not mention any specific drug by name, but it could include the GLP-1 agonists, such as ...

Popular weight-loss drugs like Wegovy or Ozempic could be covered by Medicare or Medicaid under a new rule the Biden administration proposed. The costly proposal from the U.S. Department of Health ...

A recent Health Affairs study found that expanding Medicare coverage of anti-obesity medicines could increase annual spending by $3.1 billion to $6.1 billion. The introduction of highly effective anti ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

It is not covered for weight loss by Medicare, but the FDA in early 2024 approved its use for obese patients who also have cardiovascular disease. The list cost for Wegovy is about $1,349 per ...